典型文献
Anlotinib as third-or further-line therapy for short-term relapsed small-cell lung cancer:subgroup analysis of a randomized phase 2 study(ALTER1202)
文献摘要：
Patients with small-cell lung cancer(SCLC)relapse within months after completing previous therapies.This study aimed to investigate the efficacy and safety of anlotinib as third-or further-line therapy in patients with short-term relapsed SCLC from ALTER1202.Patients with short-term relapsed SCLC(disease progression within 3 months after completing≥two lines of chemotherapy)in the anlotinib(n=67)and placebo(n=34)groups were analyzed.The primary endpoint was progression-free survival(PFS).The secondary endpoints included overall survival,objective response rate(ORR),disease control rate,and safety.Anlotinib significantly improved median PFS/OS(4.0 vs.0.7 months,P＜0.0001)/(7.3 vs.4.4 months,P=0.006)compared with placebo.The ORR was 4.5％/2.9％in the anlotinib/placebo group(P=1.000).The DCR in the anlotinib group was higher than that in the placebo group(73.1％vs.11.8％,P＜0.001).The most common adverse events(AEs)were hypertension(38.8％),loss of appetite(28.4％),and fatigue(22.4％)in the anlotinib group and gamma-glutamyl transpeptidase elevation(20.6％)in the placebo group.No grade 5 AEs occurred.For patients with short-term relapsed SCLC,third-or further-line anlotinib treatment was associated with improved survival benefit.Further studies are warranted in this regard.
文献关键词：
中图分类号：
作者姓名：
Jianhua Shi;Ying Cheng;Qiming Wang;Kai Li;Lin Wu;Baohui Han;Gongyan Chen;Jianxing He;Jie Wang;Haifeng Qin;Xiaoling Li
作者机构：
Department of Medical Oncology,Linyi Cancer Hospital,Linyi 276002,China;Department of Thoracic Medical Oncology,Jilin Cancer Hospital,Changchun 130012,China;Department of Internal Medicine,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450003,China;Department of Pulmonary Oncology,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Department of Thoracic Medical Oncology,The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University(Hunan Cancer Hospital),Changsha 410031,China;Department of Respiratory Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Respiratory Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Thoracic Surgery,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Pulmonary Oncology,The Fifth Medical Centre of Chinese PLA General Hospital,Beijing 100039,China;Department of Medical Oncology,Liaoning Cancer Hospital,Shenyang 110042,China
文献出处：
引用格式：
[1]Jianhua Shi;Ying Cheng;Qiming Wang;Kai Li;Lin Wu;Baohui Han;Gongyan Chen;Jianxing He;Jie Wang;Haifeng Qin;Xiaoling Li-.Anlotinib as third-or further-line therapy for short-term relapsed small-cell lung cancer:subgroup analysis of a randomized phase 2 study(ALTER1202))[J].医学前沿,2022(05):766-772
A类：
ALTER1202
B类：
Anlotinib,third,further,short,term,relapsed,small,cell,lung,cancer,subgroup,analysis,randomized,phase,study,Patients,SCLC,within,months,after,completing,previous,therapies,This,aimed,investigate,efficacy,safety,anlotinib,patients,from,disease,progression,two,lines,chemotherapy,placebo,groups,were,analyzed,primary,was,free,survival,PFS,secondary,endpoints,included,overall,objective,response,rate,ORR,control,significantly,improved,median,OS,compared,DCR,higher,than,that,most,common,adverse,events,AEs,hypertension,loss,appetite,fatigue,gamma,glutamyl,transpeptidase,elevation,No,grade,occurred,For,treatment,associated,benefit,Further,studies,warranted,this,regard
AB值：
0.46938
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
